Abstract
The present disclosure provides a method comprised of one or a combination of ir-lncRNA signatures to predict the clinical outcome of cancer patients, improve prognostic stratification of patients and guide cancer treatment decisions.
| Original language | English |
|---|---|
| Patent number | US2023348994 |
| IPC | C12Q 1/ 6886 A I |
| Priority date | 28/04/23 |
| Publication status | Published - 2 Nov 2023 |
Fingerprint
Dive into the research topics of 'Identification of Immune-related lncRNA Signatures with Prognostic Connotation in Multi-Cancer Setting'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver